Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
The classification of Sickle Cell Anemia Therapeutics includes Blood Transfusion, Pharmacotherapy and Bone Marrow Transplant, and the proportion of Blood Transfusion in 2017 is about 45%, and the proportion of Bone Marrow Transplant in 2017 is about 35%.
Sickle Cell Anemia Therapeutics is widely used for child and adult. The most proportion of Sickle Cell Anemia Therapeutics is for child, and the revenue share in 2017 is about 78%.
America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following America, Europe is the second largest consumption place with the consumption market share of 27%.

According to this study, over the next five years the Sickle Cell Anemia Therapeutics market will register a 10.8% CAGR in terms of revenue, the global market size will reach US$ 3620 million by 2024, from US$ 2170 million in 2019. In particular, this report presents the global revenue market share of key companies in Sickle Cell Anemia Therapeutics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Sickle Cell Anemia Therapeutics market by product type, application, key companies and key regions.

This study considers the Sickle Cell Anemia Therapeutics value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Blood Transfusion
Pharmacotherapy
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Child
Adult

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Sickle Cell Anemia Therapeutics market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Sickle Cell Anemia Therapeutics market by identifying its various subsegments.
Focuses on the key global Sickle Cell Anemia Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Sickle Cell Anemia Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Sickle Cell Anemia Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.